Patents by Inventor Peter Laing

Peter Laing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10494327
    Abstract: Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: December 3, 2019
    Assignee: United Therapeutics Corporation
    Inventor: Peter Laing
  • Patent number: 10494449
    Abstract: Polydisperse and charged polysaccharides are fractionated into low polydispersity fractions (preferably having pd<1.1), each containing species within a narrow range of molecular weights. An aqueous solution of the polydisperse polysaccharides is contacted with an ion exchange resin in a column and the polysaccharides are subjected to selective elution by aqueous elution buffer. The selective elution consists of at least 3 sequential elution buffers having different and constant ionic strength and/or pH and in which the subsequent buffers have ionic strength and/or pH than those of the preceding step. The new preparations are particularly suitable for the production of PSA-derivatised therapeutic agents intended for use in humans and animals.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: December 3, 2019
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Ioannis Papaioannou, Peter Laing
  • Publication number: 20190300580
    Abstract: The invention relates to isolated recombinant analogues of flavivirus E-protein fusion loops comprising at least one glycosylation site for an N-linked glycan that is not present in the natural flavivirus E-protein fusion loop sequence, wherein the at least one glycosylation site is an N-linked glycosylation sequon (Asn-X-Ser/Thr) and the Asn (N) residue of the sequon occupies any of positions 98-110 (DRGWGNGCGLFGK) of the natural flavivirus E-protein fusion loop amino acid sequence, wherein X is any amino acid residue except proline and Ser/Thr denotes a serine or threonine residue.
    Type: Application
    Filed: May 22, 2017
    Publication date: October 3, 2019
    Applicant: Excivion Ltd.
    Inventor: Peter LAING
  • Patent number: 10406209
    Abstract: Derivatives are synthesized of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted moiety. The derivatives may be reacted with substrates, for instance containing amine or hydrazine groups, to form non-cross-linked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs peptides or proteins or drug delivery systems.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: September 10, 2019
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Dale Howard Hreczuk-Hirst, Ioannis Papaioannou
  • Patent number: 10301396
    Abstract: The present invention relates to process for reducing the endotoxin content of a sample of fermentation broth containing polysialic acid and endotoxin comprising the sequential steps: (i) adding to the sample a base having a pKa of at least 12 to form a basic solution having a pH of at least 12, incubating the solution for a pre-determined time at a pre-determined temperature; and (ii) recovery of PSA, suitably by (iii) passing the sample through an anion-exchange column whereby polysialic acid is absorbed on the ion exchange resin; (iv) washing the column with one washing buffer, whereby polysialic acid remains absorbed on the ion exchange resin; and (v) eluting the polysialic acid from the column using an elution buffer to provide a product solution of polysialic acid having reduced endotoxin content.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: May 28, 2019
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis
  • Publication number: 20180298114
    Abstract: Polydisperse and charged polysaccharides are fractionated into low polydispersity fractions (preferably having pd 21 1.1), each containing species within a narrow range of molecular weights. An aqueous solution of the polydisperse polysaccharides is contacted with an ion exchange resin in a column and the polysaccharides are subjected to selective elution by aqueous elution buffer. The selective elution consists of at least 3 sequential elution buffers having different and constant ionic strength and/or pH and in which the subsequent buffers have ionic strength and/or pH than those of the preceding step. The new preparations are particularly suitable for the production of PSA-derivatised therapeutic agents intended for use in humans and animals.
    Type: Application
    Filed: November 22, 2017
    Publication date: October 18, 2018
    Applicant: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Ioannis Papaioannou, Peter Laing
  • Patent number: 9920137
    Abstract: A polysialic acid compound is reacted with a hetero-bifunctional reagent to introduce a pendant functional group for site-specific conjugation to sulfhydryl groups, for instance side chains of cysteine units in drugs, drug delivery systems, proteins or peptides. The functional group is, for instance, an N-maleimide group.
    Type: Grant
    Filed: July 5, 2015
    Date of Patent: March 20, 2018
    Assignee: LIPOXEN TECHNOLOGIES LIMITED
    Inventors: Dale Howard Hreczuk-Hirst, Sanjay Jain, Peter Laing, Gregory Gregoriadis, Ioannis Papaioannou
  • Publication number: 20170369416
    Abstract: Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same.
    Type: Application
    Filed: September 8, 2017
    Publication date: December 28, 2017
    Applicant: United Therapeutics Corporation
    Inventor: Peter Laing
  • Patent number: 9828443
    Abstract: Polydisperse and charged polysaccharides are fractionated into low polydispersity fractions (preferably having pd<1.1), each containing species within a narrow range of molecular weights. An aqueous solution of the polydisperse polysaccharides is contacted with an ion exchange resin in a column and the polysaccharides are subjected to selective elution by aqueous elution buffer. The selective elution consists of at least 3 sequential elution buffers having different and constant ionic strength and/or pH and in which the subsequent buffers have ionic strength and/or pH than those of the preceding step. The new preparations are particularly suitable for the production of PSA-derivatized therapeutic agents intended for use in humans and animals.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: November 28, 2017
    Assignee: LIPOXEN TECHNOLOGIES LIMITED
    Inventors: Sanjay Jain, Ioannis Papaioannou, Peter Laing
  • Patent number: 9790288
    Abstract: Polydisperse and charged polysaccharides are fractionated into low polydispersity fractions (preferably having pd<1.1), each containing species within a narrow range of molecular weights. An aqueous solution of the polydisperse polysaccharides is contacted with an ion exchange resin in a column and the polysaccharides are subjected to selective elution by aqueous elution buffer. The selective elution consists of at least 3 sequential elution buffers having different and constant ionic strength and/or pH and in which the subsequent buffers have ionic strength and/or pH than those of the preceding step. The new preparations are particularly suitable for the production of PSA-derivatised therapeutic agents intended for use in humans and animals.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: October 17, 2017
    Assignee: LIPOXEN TECHNOLOGIES LIMITED
    Inventors: Sanjay Jain, Ioannis Papaioannou, Peter Laing
  • Patent number: 9789163
    Abstract: The present invention relates to methods for producing N-terminal derivatives of proteins in which a polysaccharide, preferably having at least terminal sialic units, and preferably consisting essentially only of sialic acid units, is reacted at the N-terminus of a protein or peptide under controlled conditions to produce an N-terminal derivative. The controlled conditions include use of acidic pH for the derivatization step and a higher pH for purification. The derivatives are useful for improving pharmacokinetics and pharmacodynamics of proteins and peptides.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: October 17, 2017
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis
  • Patent number: 9758465
    Abstract: Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: September 12, 2017
    Assignee: United Therapeutics Corporation
    Inventor: Peter Laing
  • Patent number: 9750692
    Abstract: A liposomal composition, preferably a vaccine, comprising liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigen and T-cell dependent protein carrier, such as tetanus toxoid or diphtheria toxin modified to render it non-toxic. The invention is of use in the production of vaccines against Haemophilus influenzae, Streptococcus pneumoniae or Neisseria meningitidis.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: September 5, 2017
    Assignee: LIPOXEN TECHNOLOGIES LIMITED
    Inventors: Andrew David Bacon, Gregory Gregoriadis, Peter Laing
  • Publication number: 20170119893
    Abstract: The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Application
    Filed: January 12, 2017
    Publication date: May 4, 2017
    Applicant: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Norbert Oskar Rumpf
  • Publication number: 20170080054
    Abstract: The present invention relates to a compound which is a polysaccharide derivative of GCSF, or of a GCSF like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Application
    Filed: October 3, 2016
    Publication date: March 23, 2017
    Applicant: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis
  • Publication number: 20170058273
    Abstract: The present invention relates to methods for producing N-terminal derivatives of proteins in which a polysaccharide, preferably having at least terminal sialic units, and preferably consisting essentially only of sialic acid units, is reacted at the N-terminus of a protein or peptide under controlled conditions to produce an N-terminal derivative. The controlled conditions include use of acidic pH for the derivatisation step and a higher pH for purification. The derivatives are useful for improving pharmacokinetics and pharmacodynamics of proteins and peptides.
    Type: Application
    Filed: November 15, 2016
    Publication date: March 2, 2017
    Applicant: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis
  • Patent number: 9579393
    Abstract: The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: February 28, 2017
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Norbert Oskar Rumpf
  • Publication number: 20170049702
    Abstract: A composition comprising liposomes associated with a nucleic acid operatively encoding an antigenic protein and with an assistor protein, wherein the assistor protein shares at least one epitope with the antigenic protein, and wherein the nucleic acid and said assistor protein are associated with the same liposomes is described. The composition provides an improved immune response compared to mixtures of liposomes some of which are associated with the nucleic acid and some of which are associated with the assistor protein.
    Type: Application
    Filed: November 8, 2016
    Publication date: February 23, 2017
    Applicant: Lipoxen Technologies Limited
    Inventors: Andrew David Bacon, Peter Laing, Gregory Gregoriadis, Wilson Romero Caparros-Wanderley
  • Patent number: 9549990
    Abstract: The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: January 24, 2017
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Norbert Oskar Rumpf
  • Publication number: 20170007706
    Abstract: Derivatives are synthesized of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted moiety. The derivatives may be reacted with substrates, for instance containing amine or hydrazine groups, to form non-cross-linked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs peptides or proteins or drug delivery systems.
    Type: Application
    Filed: September 26, 2016
    Publication date: January 12, 2017
    Applicant: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Dale Howard Hreczuk-Hirst, Ioannis Papaioannou